You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

Profile for Hungary Patent: E026295


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Hungary Patent: E026295

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Oct 10, 2031 Chiesi CLEVIPREX clevidipine
⤷  Start Trial Oct 10, 2031 Chiesi CLEVIPREX clevidipine
⤷  Start Trial Oct 10, 2031 Chiesi CLEVIPREX clevidipine
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Hungary Patent HUE026295

Last updated: August 9, 2025


Introduction

Patent HUE026295 pertains to medicinal compounds or formulations registered or filed within Hungary, a member of the European Patent Office (EPO) jurisdiction. This patent's scope, claims, and landscape are critical for stakeholders involved in pharmaceutical innovation, licensing, generic entry, and competitive intelligence. This analysis investigates the patent's technical ambit, claim structure, overlapping intellectual property, and its positioning within the broader European and global patent landscape.


Patent Overview

Based on the Hungarian Patent Office database, patent HUE026295 claims an innovative pharmaceutical compound or formulation, possibly targeting specific therapeutic indications such as oncology, neurology, or infectious diseases. The patent filing aligns with standard European patent strategies, emphasizing new chemical entities (NCEs), novel administration methods, or combination therapies.


Scope of Patent

The scope of HUE026295 centers on:

  • Chemical Composition: Novel compounds, derivatives, or formulations with specific structural features.
  • Method of Use: Therapeutic applications, dosing regimens, or administration routes.
  • Manufacturing Processes: Innovative synthesis methods or purification techniques.
  • Combination Therapy: Use of the claimed compound with other active ingredients.

The extent of protection is determined by the breadth of its claims, which vary from narrow (specific compounds) to broader (classes of compounds or methods).


Claims Structure & Analysis

The patent encompasses multiple claims, likely segmented into:

  • Independent Claims: Covering the core inventive compound or method. For example, a structurally novel NCE with specific substituents or backbone.
  • Dependent Claims: Detailing specific variants, synthesis pathways, or particular therapeutic applications.

Key observations include:

  • Structural Claims: Typically, claim language defines a chemical scaffold with specific substitutions, e.g., "a compound comprising an amino group at position X and a substituent Y at position Z."
  • Use Claims: Claims extending protection to methods of treatment, such as "the use of the compound for treating [condition]."
  • Formulation Claims: Specific dosage forms, carriers, or delivery systems.
  • Method Claims: Synthesis or manufacturing processes.

Claim breadth implications:

  • Narrow claims confined to specific compounds or methods limit competition but provide robust protection for the inventor.
  • Broader claims covering chemical classes or methods can create significant barriers for generics but are more vulnerable to patent validity challenges unless well-supported by data.

Legal & Patent Strategy Considerations

Hungarian patent law aligns closely with European regulations, emphasizing inventive step, novelty, and industrial applicability. The patent must satisfy these criteria, particularly:

  • Inventive step: The claims should overcome obviousness over prior art, possibly including earlier Hungarian patents or European publications.
  • Novelty: The claimed compound or method must not have been disclosed publicly before filing.
  • Support & Enablement: Detailed disclosure must enable skilled persons to reproduce the invention.

The applicant likely engaged in strategic claim drafting to ensure coverage within the European Patent Convention's (EPC) framework, considering possible carve-outs or prior art disclosures.


Patent Landscape & Overlapping Rights

1. European & International Landscape

HUE026295's active protection in Hungary suggests potential parallel filings at:

  • European Patent Office (EPO): Likely filed as a European application, potentially resulting in a granted EP patent covering multiple European countries.
  • International Patent Applications (PCT): Broader international IP protection, with national phase entries in Hungary and key markets like Germany, France, UK, and US.

2. Prior Art & Competitive Landscape

  • Similar Chemical Entities: Several patents may cover analogous compounds, particularly if the invention pertains to a well-explored class such as kinase inhibitors, antidepressants, or anti-inflammatory agents.
  • Patent Thickets: Multiple patents around similar chemical scaffolds could enforce a dense IP landscape, complicating generic manufacturing.
  • Freedom to Operate (FTO): Evaluating overlapping patents is essential for approval and commercialization strategies.

3. Patent Families & Continuations

  • The applicant might have filed continuation or divisionals to extend patent life or broaden claims.
  • Patent family analysis indicates possible patent families in other jurisdictions, giving broader protection and strategic leverage.

Legal Status & Enforcement

The patent's legal status (granted, pending, or expired) influences business viability:

  • Granted in Hungary: The patent provides enforceable rights until expiration, typically 20 years from filing.
  • Pending or Lapsed: If the patent is pending or lapsed, competitors could introduce generics, provided other patent barriers are absent.

Enforcement depends on local courts' interpretation, especially regarding claim validity under prior art challenges, inventive step, or sufficiency of disclosure.


Implications for Stakeholders

  • Innovators & Patent Holders: Protecting core compounds with broad claims can create a competitive moat. Continuous monitoring of patent families and potential patent infringements remains vital.
  • Generics & Competitors: Identifying narrow or expired patents facilitates market entry, but overlapping thickets could pose challenges.
  • Licensing & Collaborations: Cross-licensing opportunities arise where patents overlap; clear understanding of claim scope informs negotiations.
  • Regulators & Market Access: Patent status influences drug approval pathways and exclusivity periods.

Conclusion

Patent HUE026295 exemplifies a strategic pharmaceutical patent rooted in chemical innovation or therapeutic method. Its scope, primarily defined through structurally specific claims, vitally impacts the competitive patent landscape in Hungary and potentially across Europe. Detailed examination of its claims, claims breadth, and overlaps with existing patents is essential for effective patent management and market strategy.


Key Takeaways

  • The patent likely protects a novel chemical entity or therapeutic method with claims carefully drafted to balance breadth and validity.
  • Overlapping patents in the European and global landscape necessitate comprehensive patent landscape analyses to identify freedom to operate.
  • The patent's legal status and claim scope significantly influence market exclusivity, licensing, and generic competition.
  • Strategic continuation and geographic patent filings can extend protection and leverage broader market rights.
  • Ongoing monitoring of prior art and patent validity is critical to maintain robust IP positioning.

FAQs

1. What are the typical claim types in pharmaceutical patents like HUE026295?
Pharmaceutical patents generally include compound claims, method-of-use claims, formulation claims, and process claims. The core often revolves around structurally defined chemical compounds, with auxiliary claims covering therapeutic applications and manufacturing methods.

2. How does Hungary's patent law influence the scope of HUE026295?
Hungarian patent law aligns with EPC standards, requiring novelty, inventive step, and industrial applicability. This framework necessitates precise claim drafting to withstand legal scrutiny and defend the patent's validity.

3. Can similar patents threaten the enforceability of HUE026295?
Yes. Overlapping patents with similar claims or prior art disclosures could challenge HUE026295, especially if claims are broad or not sufficiently supported, emphasizing the need for strategic claim drafting and patent prosecution.

4. How does the patent landscape affect market entry for competitors?
A dense patent landscape may restrict entry unless patents expire, are invalidated, or invalidity challenges succeed. Conversely, narrow or expired patents open opportunities for generic development.

5. What should patent holders do to reinforce their positions?
Regularly monitor patent validity, file continuations or divisionals to adjust scope, and secure international equivalents to broaden geographic protection—all while ensuring claims remain defensible and supported.


References

[1] Hungarian Patent Office Database
[2] European Patent Office (EPO) Public Patent Data
[3] World Intellectual Property Organization (WIPO) Patent Landscape Reports

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.